Overexpression of aldose reductase in liver cancers may contribute to drugresistance

Citation
Kwy. Lee et al., Overexpression of aldose reductase in liver cancers may contribute to drugresistance, ANTI-CANC D, 12(2), 2001, pp. 129-132
Citations number
17
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"Onconogenesis & Cancer Research
Journal title
ANTI-CANCER DRUGS
ISSN journal
0959-4973 → ACNP
Volume
12
Issue
2
Year of publication
2001
Pages
129 - 132
Database
ISI
SICI code
0959-4973(200102)12:2<129:OOARIL>2.0.ZU;2-T
Abstract
We previously found that about 29% of human liver cancers overexpressed ald ose reductase (AR) and about 54% of them overexpressed an AR-like gene call ed ARL-1 that has similar enzymatic activities to AR. Since these aldo-keto reductases can reduce a broad spectrum of substrates including cytotoxic a ldehydes, we were interested to find out if these enzymes can contribute to the resistance of liver cancer chemotherapy by inactivating some of the an ticancer drugs. HepG2 cells, a stable line of liver cells, were induced to overexpress AR by hypertonicity. Cells that were cultured in hypertonic med ium became mote resistant to daunorubicin, suggesting that overexpression o f AR made the cells more resistant to this drug. This is confirmed by the f act that addition of AR inhibitor sensitizes the cells to this drug again. This information may be important for designing new drugs to treat this dea dly disease. [(C) 2001 Lippincott Williams & Wilkins.].